Raymond James Initiates Coverage On Faeth Therapeutics with Outperform Rating, Announces Price Target of $56

Benzinga · 3d ago
Raymond James analyst Sean McCutcheon initiates coverage on Faeth Therapeutics (NASDAQ:FTH) with a Outperform rating and announces Price Target of $56.